Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038985 · ClinicalTrials.gov registry record · NA
Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis
A NA study, sponsored by AdventHealth.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02038985: Clinical Trial NA study, sponsored by AdventHealth.
NCT02038985 is a NA study that was terminated before completion, run by AdventHealth. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02038985, a NA study, was terminated before completion, sponsored by AdventHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of fluorescence imaging + Indocyanine Green (ICG) dye ("Firefly"), compared to standard white light imaging in 2D and 3D, for accurate visual diagnosis of endometriosis during a da Vinci robotically guided endometriosis resection procedure.
Primary Outcome
Quality is defined by the investigators perception of accuracy of visual diagnosis and how clear are the the resultant images used for visualization and mapping of lesions. The quality of the fluorescence imaging + ICG dye (Firefly) will be compared to standard white light imaging in 2D and 3D for accurate visual diagnosis of endometriosis during a da Vinci endometriosis resection procedure
Interventions
- OTHER Participants will receive ICG Dye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-08-16 |
| Phase | NA |
Why NCT02038985 stopped before completion
NCT02038985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Participants will receive ICG Dye is the first listed.
NCT02038985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02038985 about?
NCT02038985 is a clinical study titled "Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis". The purpose of this study is to evaluate the use of fluorescence imaging + Indocyanine Green (ICG) dye ("Firefly"), compared to standard white light imaging in 2D and 3D, for accurate visual diagnosis of endometriosis during a da Vinci robotically guided endometriosis resection procedure.
What is the current status of trial NCT02038985?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2013-06. Estimated completion is 2016-08-16.
What interventions are being tested in trial NCT02038985?
The interventions under investigation include: Participants will receive ICG Dye (OTHER).
Who is sponsoring clinical trial NCT02038985?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02038985's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia